Giuseppe D'Aiuto

TL;DR: An extended follow-up of the Italian Randomized Tamoxifen Prevention Trial shows that appropriate selection of women at high risk for hormone receptor-positive (HR+) disease may improve the risk-benefit ratio of tamoxIFen intervention.

TL;DR: The efflux rate of99mTc-sestamibi may be used for the in vivo identification of the multidrug resistant (MDR1) phenotype in untreated breast cancer patients.

TL;DR: It is suggested that occult axillary metastases might never become clinically overt and axillary dissection might be avoided in patients with small carcinomas and a clinically negative axilla and Axillary RT seems to protect the patients from axillary recurrence almost completely.

TL;DR: The ability of uPAR to physically associate with alpha(v)beta5 in the breast carcinomas examined is shown and this data suggest that uPAR directs cytoskeletal rearrangements and cell migration by altering alpha( v) beta5 signaling specificity.

TL;DR: Chemoprevention of breast cancer with tamoxifen appears to be effective in women at high risk of ER+ tumors but not among women at low risk, who may well be protected naturally by late age at menarche or early first pregnancy, or artificially by removal of the ovaries.